Investigation Report on China Anastrozole Market, 2010-2019
Description
As a non-steroidal aromatase-inhibiting, anastrozole works by inhibiting the synthesis of estrogen in post-menopausal women which can increase the severity of breast cancer. Besides, anastrozole has little influence on adrenocortical steroid or aldosterone.
Originally developed by AstraZeneca, anastrozole was approved by FDA as the second-line medicine for breast cancer in 1995 and later in 2000 became the first-line drug. In 2002, it was approved as the therapy for postmenopausal women with localized breast cancer which is ER positive.
The incidence of breast cancer has kept growing since the 1970s in the world. With decreasing fertility rate, environmental changes, increasing pressure and growing number of women aged 50-54 who face greater risk of breast cancer, the incidence of breast cancer in China grows at a rate which is 1-2% higher than that in other countries and doubles that of the world average. As the malignant tumor with the highest incidence, breast cancer will report 2.5 million cases by 2021 in China. Hence a huge market for anastrozole.
The demand for anastrozole is gradually growing. According to CRI’s market survey, anastrozole sales has went up slightly to CNY 184 million in 2014 with CAGR during the period of 2010-2014 reaching 4.89%. And AstraZeneca (US), Yangtze River Pharmaceutical Group, Huapont Pharm, Wanma Group and Hisun occupy the market, among which AstraZeneca (US) had the largest market share of about 92% for sales value in 2014.
Readers can get at least the following information through this report:
As a non-steroidal aromatase-inhibiting, anastrozole works by inhibiting the synthesis of estrogen in post-menopausal women which can increase the severity of breast cancer. Besides, anastrozole has little influence on adrenocortical steroid or aldosterone.
Originally developed by AstraZeneca, anastrozole was approved by FDA as the second-line medicine for breast cancer in 1995 and later in 2000 became the first-line drug. In 2002, it was approved as the therapy for postmenopausal women with localized breast cancer which is ER positive.
The incidence of breast cancer has kept growing since the 1970s in the world. With decreasing fertility rate, environmental changes, increasing pressure and growing number of women aged 50-54 who face greater risk of breast cancer, the incidence of breast cancer in China grows at a rate which is 1-2% higher than that in other countries and doubles that of the world average. As the malignant tumor with the highest incidence, breast cancer will report 2.5 million cases by 2021 in China. Hence a huge market for anastrozole.
The demand for anastrozole is gradually growing. According to CRI’s market survey, anastrozole sales has went up slightly to CNY 184 million in 2014 with CAGR during the period of 2010-2014 reaching 4.89%. And AstraZeneca (US), Yangtze River Pharmaceutical Group, Huapont Pharm, Wanma Group and Hisun occupy the market, among which AstraZeneca (US) had the largest market share of about 92% for sales value in 2014.
Readers can get at least the following information through this report:
- market size of anastrozole in China
- competitive landscape of anastrozole market in China
- price of anastrozole made by different enterprises in China
- market outlook of anastrozole in China
- manufacturers of anti-tumor drugs
- investors/research institutions interested in Chinese medicine market
1 RELATED CONCEPTS OF ANASTROZOLE
1.1 Indication
1.2 Sales Status in Global Market
2 MARKET PROFILE OF ANASTROZOLE IN CHINA
2.1 Patent and Approval Information of Anastrozole in China
2.2 Major Manufacturers
2.3 Market Size
3 SURVEY ON ANASTROZOLE SALES IN CHINA, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions
4 SURVEY ON MARKET SHARE OF MAJOR ANASTROZOLE MANUFACTURERS IN CHINA, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
5 SURVEY ON DOSAGE FORMS OF ANASTROZOLE IN CHINA, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume
6 REFERENCE PRICE OF ANASTROZOLE IN CHINESE HOSPITALS IN 2014
6.1 Yangtze River Pharmaceutical Group
6.2 AstraZeneca
6.3 Huapont Pharm
6.4 Wanma Group
6.5 Zhejiang Hisun Pharmaceutical Co.,Ltd.
7 MAJOR MANUFACTURERS OF ANASTROZOLE IN CHINESE MARKET, 2010-2014
7.1 AstraZeneca
7.2 Yangtze River Pharmaceutical Group
7.3 Huapont Pharm
7.4 Wanma Group
7.5 Zhejiang Hisun Pharmaceutical Co.,Ltd.
8 MARKET OUTLOOK OF ANASTROZOLE IN CHINA, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape
TABLE OF SELECTED CHARTS
Chart Approval Information of Anastrozole in China
Chart Anastrozole Sales in China
Chart Sales Value of Anastrozole in China, 2010-2014
Chart Sales Value of Anastrozole in Some Regions in China, 2010-2014
Chart Sales Volume of Anastrozole in China, 2010-2014
Chart Sales Volume of Anastrozole in Some Regions in China, 2010-2014
Chart Market Share of TOP5 Anastrozole Manufacturers for Sales Value in China, 2010-2014
Chart Sales Value and Market Share of Anastrozole Made by AstraZeneca (US) in China, 2010-2014
Chart Sales Value and Market Share of Anastrozole Made by Yangtze River Pharmaceutical Group in China, 2010-2014
Chart Sales Value and Market Share of Anastrozole Made by Huapont in China, 2010-2014
Chart Sales Value and Market Share of Anastrozole Made by Other Manufacturers in China, 2010-2014
Chart Price of Anastrozole Made by Yangtze River Pharmaceutical Group in Some Chinese Cities in 2014
Chart Price of Anastrozole Made by AstraZeneca (US) in Some Chinese Cities in 2014
Chart Price of Anastrozole Made by Huapont in Some Chinese Cities in 2014
Chart Price of Anastrozole Made by Wanma Group in Some Chinese Cities in 2014
Chart Price of Anastrozole Made by Hisun in Some Chinese Cities in 2014
COMPANIES MENTIONED
Yangtze River Pharmaceutical Group; AstraZeneca; Huapont Pharm; Wanma Group; Zhejiang Hisun Pharmaceutical Co.,Ltd.
1.1 Indication
1.2 Sales Status in Global Market
2 MARKET PROFILE OF ANASTROZOLE IN CHINA
2.1 Patent and Approval Information of Anastrozole in China
2.2 Major Manufacturers
2.3 Market Size
3 SURVEY ON ANASTROZOLE SALES IN CHINA, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions
4 SURVEY ON MARKET SHARE OF MAJOR ANASTROZOLE MANUFACTURERS IN CHINA, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
5 SURVEY ON DOSAGE FORMS OF ANASTROZOLE IN CHINA, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume
6 REFERENCE PRICE OF ANASTROZOLE IN CHINESE HOSPITALS IN 2014
6.1 Yangtze River Pharmaceutical Group
6.2 AstraZeneca
6.3 Huapont Pharm
6.4 Wanma Group
6.5 Zhejiang Hisun Pharmaceutical Co.,Ltd.
7 MAJOR MANUFACTURERS OF ANASTROZOLE IN CHINESE MARKET, 2010-2014
7.1 AstraZeneca
7.2 Yangtze River Pharmaceutical Group
7.3 Huapont Pharm
7.4 Wanma Group
7.5 Zhejiang Hisun Pharmaceutical Co.,Ltd.
8 MARKET OUTLOOK OF ANASTROZOLE IN CHINA, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape
TABLE OF SELECTED CHARTS
Chart Approval Information of Anastrozole in China
Chart Anastrozole Sales in China
Chart Sales Value of Anastrozole in China, 2010-2014
Chart Sales Value of Anastrozole in Some Regions in China, 2010-2014
Chart Sales Volume of Anastrozole in China, 2010-2014
Chart Sales Volume of Anastrozole in Some Regions in China, 2010-2014
Chart Market Share of TOP5 Anastrozole Manufacturers for Sales Value in China, 2010-2014
Chart Sales Value and Market Share of Anastrozole Made by AstraZeneca (US) in China, 2010-2014
Chart Sales Value and Market Share of Anastrozole Made by Yangtze River Pharmaceutical Group in China, 2010-2014
Chart Sales Value and Market Share of Anastrozole Made by Huapont in China, 2010-2014
Chart Sales Value and Market Share of Anastrozole Made by Other Manufacturers in China, 2010-2014
Chart Price of Anastrozole Made by Yangtze River Pharmaceutical Group in Some Chinese Cities in 2014
Chart Price of Anastrozole Made by AstraZeneca (US) in Some Chinese Cities in 2014
Chart Price of Anastrozole Made by Huapont in Some Chinese Cities in 2014
Chart Price of Anastrozole Made by Wanma Group in Some Chinese Cities in 2014
Chart Price of Anastrozole Made by Hisun in Some Chinese Cities in 2014
COMPANIES MENTIONED
Yangtze River Pharmaceutical Group; AstraZeneca; Huapont Pharm; Wanma Group; Zhejiang Hisun Pharmaceutical Co.,Ltd.
